Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | The impact of lenalidomide on second primary malignancies: long-term data from the Myeloma XI Trial

Gareth Morgan • 11 Dec 2022
ASH 2022
Multiple Myeloma Lenalidomide

Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York City, NY, shares the results of a study evaluating the impact of lenalidomide on second primary malignancies (SPM) development when used at induction and maintenance therapy for patients with multiple myeloma. Overall, the data demonstrated that there was very little risk of SPM development with lenalidomide, with only a few incidences of skin cancer recorded. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Gareth Morgan

2:19
How cutting-edge research is changing outcomes in myeloma and the need for novel endpoints in trials
Gareth Morgan • 10 Dec 2023
1:48
Investigating the non-coding myeloma genome
Gareth Morgan • 10 Dec 2023
1:29
Structural variation is a key driver of relapse and aggressive clinical behavior in multiple myeloma
Gareth Morgan • 10 Dec 2023
1:46
Personalizing treatment in multiple myeloma: approaching patients with t(4;14) and t(11;14)
Gareth Morgan • 29 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals